Valuation: ADC Therapeutics SA

Market Cap 13Cr 12Cr 11Cr 9.91Cr 19Cr 1.27TCr 19Cr 127Cr 50Cr 634.47Cr 50Cr 49Cr 2.1TCr P/E 2026 *
-1.23x
P/E 2027 * -1.58x
Enterprise Value 13Cr 12Cr 11Cr 9.91Cr 19Cr 1.27TCr 19Cr 127Cr 50Cr 634.47Cr 50Cr 49Cr 2.1TCr EV / Sales 2026 *
1.65x
EV / Sales 2027 * 1.08x
Free-Float
83.84%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: ADC Therapeutics SA

1 day-5.41%
1 week-13.93%
Current month-1.87%
1 month-1.87%
3 months-72.22%
6 months-70.91%
Current year-70.25%
1 week 1.04
Extreme 1.045
1.21
1 month 1.04
Extreme 1.045
1.46
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.36
Extreme 0.3599
6.04
5 years 0.36
Extreme 0.3599
32
10 years 0.36
Extreme 0.3599
56.59
Manager TitleAgeSince
Chief Executive Officer 53 09/05/2022
Director of Finance/CFO 54 19/12/2022
Chief Tech/Sci/R&D Officer 52 01/10/2024
Director TitleAgeSince
Director/Board Member 67 01/06/2019
Director/Board Member 53 01/06/2018
Chairman 59 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Chief Executive Officer

6,75,000 0.5307%
30/06/26 Free

Chief Financial Officer

2,03,700 0.1602%
30/06/26 Free

Chief Technology Officer

2,13,900 0.1682%
Change 5-day change 1-year change 3-year change Capi.($)
-5.41%-13.93%-64.29%-17.97% 14Cr
+2.35%+0.77%+29.92%+85.38% 5.52TCr
-0.21%-6.52%+42.39%+64.10% 5.38TCr
-2.44%-1.61%-17.69%-15.68% 2.35TCr
-2.85%-8.20%-6.26%+361.83% 2.2TCr
+2.49%-1.27%+15.99%-10.53% 1.98TCr
+0.79%-2.39%+26.99%-31.34% 1.74TCr
+0.58%-7.23%+24.50%+519.07% 1.47TCr
-5.25%-4.71%+43.89%+167.15% 1.41TCr
+3.41%-7.83%+161.76%+284.91% 1.3TCr
Average -0.65%-2.42%+25.72%+140.69% 2.34TCr
Weighted average by Cap. +0.17%+0.09%+30.99%+122.72%

Financials

2026 *2027 *
Net sales 8.09Cr 7.02Cr 6.53Cr 6Cr 11Cr 771.54Cr 12Cr 77Cr 30Cr 384.3Cr 30Cr 30Cr 1.27TCr 12Cr 11Cr 10Cr 9.19Cr 17Cr 1.18TCr 18Cr 117.74Cr 46Cr 588.22Cr 46Cr 45Cr 1.95TCr
Net income -14Cr -12Cr -11Cr -10Cr -19Cr -1.3TCr -19Cr -129.45Cr -51Cr -646.73Cr -51Cr -50Cr -2.14TCr -12Cr -10Cr -9.47Cr -8.7Cr -16Cr -1.12TCr -17Cr -111.56Cr -44Cr -557.34Cr -44Cr -43Cr -1.85TCr
Net Debt - -
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
31/26/31 $1.050 -5.41% 7,55,742
30/26/30 $1.110 +0.91% 8,87,735
29/26/29 $1.100 -0.90% 9,24,496
28/26/28 $1.110 -2.63% 7,47,766
27/26/27 $1.140 -0.87% 7,87,746
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.050USD
Average target price
5.000USD
Spread / Average Target
+376.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADCT Stock